(Q37502708)

20 August 2017

1 reference

title

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. (English)

1 reference

20 August 2017

Helena Linardou

1

1 reference

20 August 2017

Issa J Dahabreh

2

1 reference

20 August 2017

Dimitrios Bafaloukos

3

1 reference

20 August 2017

Paris Kosmidis

4

1 reference

20 August 2017

Samuel Murray

5

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Nature Reviews Clinical Oncology

20 August 2017

1 reference

20 August 2017

6

1 reference

20 August 2017

352-366

1 reference

20 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2009.62

20 August 2017

0 references

cites work

Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Cetuximab in the treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

EGFR antagonists in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Epidermal growth factor receptor: mechanisms of activation and signalling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Epidermal growth factor receptor (EGFR) signaling in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

EGFR and cancer prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Untangling the ErbB signalling network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gefitinib--a novel targeted approach to treating cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Equitable Allocation of Antiretrovirals in Resource-Constrained Countries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Epidermal growth factor receptor mutations in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Cancer. Addiction to oncogenes--the Achilles heal of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Therapy options in imatinib failures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Erlotinib in lung cancer - molecular and clinical predictors of outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Epidermal growth factor receptor mutation testing in the care of lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

EGFR mutation and response of lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Detection of mutations in EGFR in circulating lung-cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Somatic mutations affect key pathways in lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

What do we mean by validating a prognostic model?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.62

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

31 March 2020

1 reference

12 December 2020

Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.

1 reference

12 December 2020

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

1 reference

12 December 2020

Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

1 reference

12 December 2020

Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature

1 reference

12 December 2020

Assessing EGFR mutations

1 reference

12 December 2020

10.1038/NRCLINONC.2009.62

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference